JP2022546878A5 - - Google Patents

Info

Publication number
JP2022546878A5
JP2022546878A5 JP2022540618A JP2022540618A JP2022546878A5 JP 2022546878 A5 JP2022546878 A5 JP 2022546878A5 JP 2022540618 A JP2022540618 A JP 2022540618A JP 2022540618 A JP2022540618 A JP 2022540618A JP 2022546878 A5 JP2022546878 A5 JP 2022546878A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutically acceptable
isovaleric acid
acceptable salt
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022540618A
Other languages
English (en)
Japanese (ja)
Other versions
JP7831841B2 (ja
JP2022546878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049244 external-priority patent/WO2021046246A1/en
Publication of JP2022546878A publication Critical patent/JP2022546878A/ja
Publication of JP2022546878A5 publication Critical patent/JP2022546878A5/ja
Priority to JP2025128508A priority Critical patent/JP2025163134A/ja
Application granted granted Critical
Publication of JP7831841B2 publication Critical patent/JP7831841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022540618A 2019-09-03 2020-09-03 コンジュゲートされたヘプシジン模倣物 Active JP7831841B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025128508A JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US62/895,201 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US62/983,515 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US63/020,945 2020-05-06
US202063059747P 2020-07-31 2020-07-31
US63/059,747 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025128508A Division JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Publications (3)

Publication Number Publication Date
JP2022546878A JP2022546878A (ja) 2022-11-09
JP2022546878A5 true JP2022546878A5 (cg-RX-API-DMAC10.html) 2023-09-11
JP7831841B2 JP7831841B2 (ja) 2026-03-17

Family

ID=74681239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022540618A Active JP7831841B2 (ja) 2019-09-03 2020-09-03 コンジュゲートされたヘプシジン模倣物
JP2025128508A Pending JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025128508A Pending JP2025163134A (ja) 2019-09-03 2025-07-31 コンジュゲートされたヘプシジン模倣物

Country Status (16)

Country Link
US (2) US20220372099A1 (cg-RX-API-DMAC10.html)
EP (2) EP4706671A3 (cg-RX-API-DMAC10.html)
JP (2) JP7831841B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220075343A (cg-RX-API-DMAC10.html)
CN (1) CN114729022A (cg-RX-API-DMAC10.html)
AU (2) AU2020343328B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003999A2 (cg-RX-API-DMAC10.html)
CA (1) CA3152789A1 (cg-RX-API-DMAC10.html)
DK (1) DK4025592T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058577T3 (cg-RX-API-DMAC10.html)
FI (1) FI4025592T3 (cg-RX-API-DMAC10.html)
IL (1) IL291030A (cg-RX-API-DMAC10.html)
MX (1) MX2022002633A (cg-RX-API-DMAC10.html)
PH (1) PH12022550510A1 (cg-RX-API-DMAC10.html)
PL (1) PL4025592T3 (cg-RX-API-DMAC10.html)
WO (1) WO2021046246A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2022212696A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
US20250170216A1 (en) * 2022-02-02 2025-05-29 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR20170002414A (ko) * 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
AU2017324446A1 (en) 2016-09-06 2019-03-28 La Jolla Pharmceutical Company Methods of treating iron overload
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Similar Documents

Publication Publication Date Title
JP2025163134A5 (cg-RX-API-DMAC10.html)
JP2024520861A5 (cg-RX-API-DMAC10.html)
JP7831841B2 (ja) コンジュゲートされたヘプシジン模倣物
JP6279626B2 (ja) エンドモルフィンのμオピオイド受容体アゴニスト類似体
AU2014228460B2 (en) Pharmaceutical compositions
US10335455B2 (en) Method for prevention or treatment of intractable inflammatory bowel disease
US20240293511A1 (en) Hepcidin mimetics for treatment of hereditary hemochromatosis
MX2014012625A (es) Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
WO2018128828A1 (en) Novel hepcidin mimetics and uses thereof
US11414474B2 (en) Long-acting adrenomedullin derivatives
JP2016515620A5 (cg-RX-API-DMAC10.html)
PT1971362E (pt) Exendina para tratamento de diabetes e redução do peso corporal
JP2016518351A5 (cg-RX-API-DMAC10.html)
Klein et al. Pressor and cardioaccelerator effects of gamma MSH and related peptides
EP1976548B1 (en) VIP fragments and compositions thereof
EP1651662A2 (en) Antagonistic analogs of gh-rh (2003)
WO2024011188A1 (en) Combination therapy for treatment of iron overload diseases
JPH0753591A (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
WO1991010681A1 (en) Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
CA2543507A1 (en) Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
JPH0770178A (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
US6316414B1 (en) Somatostatin analogs for the treatment of cancer
JPH09502971A (ja) Crohn’s病および/または潰瘍性大腸炎の治療もしくは予防
CN115414468B (zh) 一种趋化素样因子1衍生肽在制备镇痛制剂中的应用
EP1549334B1 (en) Pharmaceutical composition comprising a retro-inverso isomer peptide